Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.550
+0.160 (11.51%)
Sep 18, 2025, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Lineage Cell Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.25, which forecasts a 174.19% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $9.00.
Price Target: $4.25 (+174.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +29.03% | Aug 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +29.03% | Aug 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +29.03% | Aug 5, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +29.03% | Jun 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +480.65% | Jun 23, 2025 |
Financial Forecast
Revenue This Year
8.81M
from 9.50M
Decreased by -7.27%
Revenue Next Year
24.31M
from 8.81M
Increased by 176.00%
EPS This Year
-0.15
from -0.09
EPS Next Year
-0.07
from -0.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.3M | 44.7M | |||
| Avg | 8.8M | 24.3M | |||
| Low | 6.1M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.4% | 407.8% | |||
| Avg | -7.3% | 176.0% | |||
| Low | -36.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.07 | - | |||
| Avg | -0.15 | -0.07 | |||
| Low | -0.21 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.